scholarly article | Q13442814 |
P50 | author | Sara Brucker | Q63345510 |
Peter A. Fasching | Q64005064 | ||
Matthias W. Beckmann | Q72940290 | ||
Peyman Hadji | Q112631966 | ||
Andreas Schneeweiss | Q37074948 | ||
Michael P. Lux | Q37372079 | ||
P2093 | author name string | Diethelm Wallwiener | |
Volkmar Müller | |||
Johannes Ettl | |||
Achim Wöckel | |||
Markus Wallwiener | |||
Hans Tesch | |||
Wolfgang Janni | |||
Diana Lüftner | |||
Andreas D Hartkopf | |||
Tanja N Fehm | |||
Florin-Andrei Taran | |||
Florian Schütz | |||
Erik Belleville | |||
Friedrich Overkamp | |||
Hans-Christian Kolberg | |||
Naiba Nabieva | |||
P2860 | cites work | RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. | Q39670403 |
Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods | Q41011976 | ||
Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients | Q42013702 | ||
Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. | Q42236299 | ||
Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors | Q42599064 | ||
Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis | Q44896647 | ||
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment | Q45060789 | ||
Association analysis identifies 65 new breast cancer risk loci. | Q45979098 | ||
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | Q46103372 | ||
Body mass index and breast cancer survival: a Mendelian randomization analysis | Q46115524 | ||
Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer | Q46782579 | ||
Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium | Q47190168 | ||
Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. | Q50089754 | ||
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. | Q50866974 | ||
Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians | Q84897741 | ||
The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast | Q86050224 | ||
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | Q28584533 | ||
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer | Q29417100 | ||
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials | Q30982699 | ||
Breast Cancer Risk - Genes, Environment and Clinics | Q34201805 | ||
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer | Q34996647 | ||
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network | Q35054455 | ||
19p13.1 is a triple-negative-specific breast cancer susceptibility locus | Q35871567 | ||
RAD51B in Familial Breast Cancer | Q36009422 | ||
The contributions of breast density and common genetic variation to breast cancer risk | Q36137764 | ||
Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization | Q36276540 | ||
Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk | Q36600605 | ||
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer | Q36859142 | ||
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. | Q37130218 | ||
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation | Q37342144 | ||
Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer | Q37374245 | ||
RANKL/RANK control Brca1 mutation-driven mammary tumors | Q37457304 | ||
Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis | Q37660589 | ||
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer | Q37706111 | ||
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. | Q38393045 | ||
COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy | Q38439080 | ||
Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry | Q38606464 | ||
Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. | Q38636290 | ||
Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy | Q38699879 | ||
BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer | Q38914005 | ||
Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment | Q39046820 | ||
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | Q39348799 | ||
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers | Q39437211 | ||
P433 | issue | 3 | |
P304 | page(s) | 246-259 | |
P577 | publication date | 2018-03-21 | |
P1433 | published in | Geburtshilfe und Frauenheilkunde: Ergebnisse der Forschung für die Praxis | Q26841999 |
P1476 | title | Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. | |
P478 | volume | 78 |
Q90285490 | Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study |
Q61795805 | Mechanisms of Metastasis and Cell Mobility – The Role of Metabolism |
Q58101133 | Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer |
Q90547034 | RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women |
Q61814603 | Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry |
Q52632717 | Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers. |
Q59335358 | Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer |
Q59335362 | Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer |
Q64102991 | Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice |
Q58587476 | [TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes] |
Search more.